285 related articles for article (PubMed ID: 16789334)
1. FDA electronic drug labels to improve patient safety.
J Pain Palliat Care Pharmacother; 2006; 20(2):96-7. PubMed ID: 16789334
[No Abstract] [Full Text] [Related]
2. Getting SMART (submission management and review tracking) drug review in the computer age.
Flieger K
FDA Consum; 1995 Oct; 29(8):6-9. PubMed ID: 10151839
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.
Frueh FW; Amur S; Mummaneni P; Epstein RS; Aubert RE; DeLuca TM; Verbrugge RR; Burckart GJ; Lesko LJ
Pharmacotherapy; 2008 Aug; 28(8):992-8. PubMed ID: 18657016
[TBL] [Abstract][Full Text] [Related]
4. Sources of drug information: FDA-approved labeling and other official FDA sources.
Lindstrom JA
Dermatol Ther; 2009; 22(3):246-56. PubMed ID: 19453349
[TBL] [Abstract][Full Text] [Related]
5. Leavitt: reforms will improve oversight and openness at FDA.
FDA Consum; 2005; 39(3):37. PubMed ID: 16127819
[TBL] [Abstract][Full Text] [Related]
6. Drug recalls and notification of practitioners.
Rodts MF
Orthop Nurs; 2004; 23(6):353-4. PubMed ID: 15682877
[No Abstract] [Full Text] [Related]
7. The new Food and Drug Administration drug package insert: implications for patient safety and clinical care.
Watson KT; Barash PG
Anesth Analg; 2009 Jan; 108(1):211-8. PubMed ID: 19095852
[TBL] [Abstract][Full Text] [Related]
8. FDA proposes patient package inserts for most drugs.
Mayberger HW; Bell BJ
Leg Aspects Med Pract; 1979 Oct; 7(10):42-4. PubMed ID: 263192
[No Abstract] [Full Text] [Related]
9. The FDA announces new prescription drug information format.
FDA Consum; 2006; 40(2):25-7. PubMed ID: 16671197
[TBL] [Abstract][Full Text] [Related]
10. FDA-USP drug product problem reporting program--an update.
Wheatley LS
Hosp Formul; 1979 Mar; 14(3):359-60, 365. PubMed ID: 10316797
[No Abstract] [Full Text] [Related]
11. Boxed warnings and other FDA communication tools.
Marks NS; Weiss K
Am Fam Physician; 2010 Feb; 81(3):259. PubMed ID: 20112882
[No Abstract] [Full Text] [Related]
12. Patient package inserts: the proper prescription?
Rowe HM
Food Drug Law J; 1995; 50(1):95-124. PubMed ID: 10342988
[No Abstract] [Full Text] [Related]
13. Safety-related drug labeling changes approved by FDA.
White GG
J Toxicol Clin Toxicol; 1998; 36(3):265-7. PubMed ID: 9678979
[No Abstract] [Full Text] [Related]
14. Pharmacogenomic biomarkers in drug labels: what do they tell us?
Tutton R
Pharmacogenomics; 2014 Feb; 15(3):297-304. PubMed ID: 24533709
[TBL] [Abstract][Full Text] [Related]
15. What drug labels don't tell you.
Consum Rep; 2011 Aug; 76(8):10. PubMed ID: 21770080
[No Abstract] [Full Text] [Related]
16. Educating patients about their medications: the potential and limitations of written drug information.
Shrank WH; Avorn J
Health Aff (Millwood); 2007; 26(3):731-40. PubMed ID: 17485751
[TBL] [Abstract][Full Text] [Related]
17. Lessons from cisapride.
CMAJ; 2001 May; 164(9):1269, 1271. PubMed ID: 11341130
[No Abstract] [Full Text] [Related]
18. Generic drug scandals raise questions about safety. FDA reorganizes to increase surveillance, prevent fraud.
Martin S
Am Pharm; 1989 Oct; NS29(10):23-4. PubMed ID: 2816714
[No Abstract] [Full Text] [Related]
19. Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium.
Anthony M; Romero K; Malone DC; Hines LE; Higgins L; Woosley RL
Clin Pharmacol Ther; 2009 Oct; 86(4):425-9. PubMed ID: 19587643
[TBL] [Abstract][Full Text] [Related]
20. A defense of the learned intermediary doctrine.
Goetz RB; Growdon KR
Food Drug Law J; 2008; 63(2):421-38. PubMed ID: 18561470
[No Abstract] [Full Text] [Related]
[Next] [New Search]
